Avalyn Pharma (AVLN) Stock Analysis
NASDAQHealthcareBiotechnology
What Avalyn Pharma does
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Key metrics
ETFs linked to AVLN
Broad-market and Healthcare sector ETFs an investor holding Avalyn Pharma is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how AVLN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze AVLN in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Avalyn Pharma?
- Avalyn Pharma trades under the ticker AVLN on NASDAQ.
- Which exchange is AVLN listed on?
- AVLN is listed on NASDAQ.
- What sector does Avalyn Pharma operate in?
- Avalyn Pharma is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze AVLN in a portfolio?
- PortView shows AVLN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.